Performance of plasma amyloid, tau, and astrocyte biomarkers to identify cerebral AD pathophysiology

Pâmela C. L. Ferreira¹, Cécile Tissot^{1,2,3}, João Pedro Ferrari-Souza^{1,4}, Wagner S. Brum^{4,5,6}, Bruna Bellaver^{1,4}, Douglas T. Leffa^{2,3}, Joseph Therriault^{2,3}, Andréa L. Benedet^{2,3}, Firoza Z. Lussier^{2,3}, Mira Chamoun^{2,3}, Gleb Bezgin^{2,3}, Stijn Servaes^{2,3}, Jenna Stevenson^{2,3}, Nesrine Rahmouni^{2,3}, Vanessa Pallen^{2,3}, Min Su Kang^{2,3}, Nina Margherita Poltronetti^{2,3}, Dana L. Tudorascu¹, William E. Klunk¹, Victor L. Villemagne¹, Annie Cohen¹, Serge Gauthier², Eduardo R. Zimmer^{4,8,9}, Nicholas J. Ashton^{5,10,11,12}, Henrik Zetterberg^{5,6,13,14,15}, Kaj Blennow^{5,6}, Thomas K. Karikari^{1,5,6}, Pedro Rosa-Neto^{2,3,†}, and Tharick A. Pascoal^{1,*†}

¹Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.

²Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal

³Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada.

⁴Graduate Program in Biological Sciences: Biochemistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.

⁵Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.

⁶Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Gothenburg, Sweden.

⁷ADHD Outpatient Program & Development Psychiatry Program, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.

⁸Department of Pharmacology, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.

⁹Graduate Program in Biological Sciences: Pharmacology and Therapeutics, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.

¹⁰Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Gothenburg, Sweden.

¹¹Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.

¹²Department of Old Age Psychiatry, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.

¹³Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.

¹⁴UK Dementia Research Institute at UCL, London, UK.

¹⁵Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

†Contributed equally

***Corresponding author:**

Tharick A Pascoal, PhD

Assistant Professor of Psychiatry and Neurology

University of Pittsburgh

3501 Forbes Ave, Pittsburgh, PA 15213

Phone number: +1 412 246 5147

pascoal@pitt.edu

Abstract

Introduction: Plasma amyloid- β (A β), phosphorylated tau (p-tau), and glial fibrillar acid protein (GFAP) can identify Alzheimer's disease (AD) pathophysiology with high accuracy. However, comparing their performance in the same individuals remains under-explored.

Methods: We compared the predictive performance of plasma A β 42/40, p-tau(at threonine 181 and 231), neurofilament light (NfL), and GFAP to identify A β - and tau-PET positivity in 138 cognitive unimpaired (CU) and 87 cognitive impaired (CI) individuals.

Results: In CU, plasma p-tau231 had the best performance to identify both A β - and tau-PET positivity. In CI, plasma GFAP showed the best predictive accuracy to identify both A β and tau-PET positivity.

Discussion: Our results support plasma p-tau231 as a marker of early AD pathology and, that GFAP best identifies both PET A β and tau abnormalities in the brain of CI individuals. These findings highlight that the performance of blood-based protein biomarkers to identify the presence of AD pathophysiology is disease-stage dependent.

Keywords: blood biomarkers; amyloid- β ; tau; phosphorylated tau; astrocyte; Alzheimer's disease.

1. Introduction

The pathological hallmarks of Alzheimer's disease (AD) are brain deposits of amyloid- β (A β) plaques and tau neurofibrillary tangles [1]. Measuring A β and tau levels in living subjects can increase clinicians' diagnostic accuracy when assessing cognitively impaired (CI) patients [2] and can inform the risk of progression to dementia in cognitively unimpaired (CU) individuals [3]. Reduction of A β 42/40 and increased tau [both total (t-tau) and phosphorylated tau (p-tau)] levels are the cerebrospinal fluid (CSF) biomarker signature of AD [4]. Similarly, positron emission tomography (PET) imaging can also be used for the visual identification and quantification of A β [5] and tau [6] aggregates. Although A β and tau can be accurately identified by CSF and PET [4, 7], these biomarker modalities' costs, accessibility and relative invasiveness limit their use in clinical practice and trials. Thus, there is an urgent need for accessible and cost-effective blood methods to accurately identify these key AD processes. In fact, several studies demonstrated that A β , p-tau, neurofilament light (NfL), and glial fibrillary acidic protein (GFAP) levels are highly associated with the presence of AD hallmark proteinopathies in the human brain [8-19].

Plasma A β can be quantified by immunoprecipitation coupled to mass spectrometry (IP-MS) and by novel ultrasensitive immunoassay techniques [20-23], including fully automated clinical chemistry instruments [24]. Both methods can detect with relatively high precision individuals with abnormal brain A β burden or those at high risk of future conversion to A β -PET positivity [11, 20, 21, 23, 25]. More recently, plasma levels of tau protein phosphorylated at threonine 181 (p-tau181), 217 (p-tau217), and 231 (p-tau231) have shown high accuracy to detect both tau and A β pathologies [8, 11, 13]. Analysis of these three p-tau epitopes has shown comparable diagnostic accuracy for AD dementia, whereas p-tau-217 and p-tau231 has been suggested as a marker of early AD pathology [8, 11, 13, 26]. Although p-tau epitopes directly measure tau pathology, the fact that some epitopes become hyperphosphorylated in response to initial A β aggregation [27] suggesting that these markers would be more accurate than plasma A β to detect brain amyloidosis [8, 13]. NfL is a well-validated biomarker for tracking neurodegeneration and neuronal injury that has been shown to correlate with A β and tau but is not specific to AD, as abnormal levels are also described in several other neurodegenerative disorders [19, 28-31]. Studies have recently shown that plasma GFAP, a marker of astrocyte reactivity, can detect with high accuracy A β -PET positivity [10, 16, 32]. The high correlation

has been attributed to the fact that astrocytes may show increased expression of GFAP in regions surrounding A β plaques [14, 33]. Although several studies have shown a strong correlation between the markers mentioned above and brain A β and tau levels, no previous study has directly compared the plasma performance of all these markers in the same individuals.

Here, we compared the performance of plasma A β , p-tau, GFAP, and NfL alone and in combination with demographics to identify both brain A β and tau pathology measured with PET in CU and CI individuals. We hypothesize that the performance of each biomarker will depend on the patient's disease clinical stage.

2. Methods

2.1 Study participants

We assessed 225 individuals [138 CU elderly adults, 53 mild cognitive impairment (MCI) subjects and 34 AD dementia patients] from the Translational Biomarkers of Aging and Dementia (TRIAD) cohort of McGill University, Canada [34]. The participants underwent clinical and neuropsychological assessments, including Mini-Mental State Examination (MMSE) and the Clinical Dementia Rating (CDR). CU participants had a CDR score of 0 and no objective cognitive impairment. Participants with Mild cognitive impairment (MCI) had subjective and objective cognitive impairments CDR score of 0.5, and preserved activities of daily living. Alzheimer's disease patients had a CDR score between 0.5 and 2 and met the National Institute on Aging and the Alzheimer's Association criteria for probable Alzheimer's disease determined by a physician [35]. For this study, individuals with a diagnosis of AD or MCI were classified as CI. Details on the information gathered from participants can be found here: <https://triad.tnl-mcgill.com/>.

2.2 Neuroimaging

Study participants had magnetic resonance imaging 3D T1-weighted MRI (3 T Siemens), tau [^{18}F]MK6240 PET and A β [^{18}F]AZD4694 PET scans with a brain-dedicated Siemens High Resolution Research Tomograph at the Montreal Neurological Institute. The acquisition and processing of the images followed standard protocols [34]. Braak stages were calculated according to previously described methods [36]. We considered individuals tau-PET positive (T+) if they were Braak stage II or above. Global [^{18}F]AZD4694 standardized uptake value ratio (SUVR) value was estimated from the precuneus, prefrontal, orbitofrontal, parietal,

temporal, anterior and posterior cingulate cortices [37]. We used the published [^{18}F]AZD4694 cut-off value of 1.55 global SUVR [34] to classify the participants as A β positive (A+) or A β negative (A-).

2.3 Plasma measurements

Plasma p-tau181, p-tau231 and NfL were measured using in-house Single molecule array (Simoa) methods on an HD-X instrument (Quanterix, Billerica, MA, USA) at the Clinical Neurochemistry Laboratory, University of Gothenburg, Mölndal, Sweden [8, 38, 39]. Plasma GFAP was measured by the Simoa method using the commercial single-plex assay (No. 102336), while the plasma A β 42, A β 40 were quantified using a multiplexed assay. In addition, plasma A β 42 and A β 40 were measured using an IP-MS method with a previously described method [40].

2.4 Statistical analysis

Statistical analyses were performed using R statistical software version 4.0.5 (<http://www.r-project.org/>). The demographic characteristics considered in the statical analysis were sex, age, and apolipoprotein E4 (*APOE* ϵ 4) carriage status. Voxel-wise statistics were conducted using MATLAB software version 9.2 (<http://www.mathworks.com>) with the VoxelStats package [41]. Descriptive statistics, including means and standard deviations, were calculated for CU and CI groups, and comparisons were performed using Student t-tests for continuous variables and chi-square tests for the categorical ones. The association between the plasma biomarkers was assessed using Pearson correlations and linear regressions. In the ROI-based multiple regression models, partial residuals generated with the R function `termplot` were used to graphically represent the investigated associations [42]. Model goodness-of-fit was evaluated using R-square analyses. Building from basic demographics including age, sex, and *APOE* ϵ 4 genotype as predictors, we sequentially added plasma biomarkers in all possible combinations and evaluated models' performance alone and in combination with demographics. We assessed and compared the discriminative performances of each model using receiver operating characteristic (ROC) and area under the curve (AUC) with the DeLong test. Statistical significance was set as $p < 0.05$ after considering Bonferroni correction for multiple comparison tests.

3. Results

3.1 Participant Characteristics and Biomarker profile

In the CU group, 23.1% of individuals were A+ and 17.0% were T+. In the CI group, 81.0% were A β + and 72.0 % were Tau+. The concentrations of p-tau231 and GFAP were 1.5-fold higher in the CI compared to the CU group ($P < 0.0001$). Similarly, p-tau181 concentrations were 1.7-fold higher in the CI group ($P < 0.0001$) and NfL concentrations were 1.2-fold higher in the CI group ($P = 0.01$). Simoa and IP-MS A β 42/40 were not significantly different between diagnostic groups. We also compared the groups regarding their A and T status, and the results remain similar. Demographic and biomarkers characteristics of the population are summarized in **Table 1**.

3.2 Correlations Between Plasma Biomarkers

Pearson correlations coefficients between plasma biomarkers are shown in **Figure 1**. In the CU group, associations between plasma p-tau181 and p-tau231 measures ($P < 0.0001$), as well as GFAP with NfL ($P < 0.0001$) were statistically significant after multiple comparison correction. A β 42/40 (Simoa and IP-MS) were not associated with each other or any other plasma marker. In the CI group, the correlation between p-tau, GFAP and NfL measures were significant ($P < 0.0001$). A β 42/40 (Simoa/IP-MS) were not associated with each other or the other plasma markers.

3.3 Voxel-wise association of A β -PET SUVR with plasma biomarkers

We performed voxel-wise linear regression between plasma markers and A β -PET SUVR in the CU and CI groups accounting for demographics. In the CU group, voxel-wise regression showed a significant positive association between A β -PET SUVR and plasma p-tau (p-tau231>p-tau181) and GFAP concentrations in the temporal and frontal cortices (**Figure 2A**). No significant voxel-wise associations were found between A β -PET and plasma A β 42/40 (Simoa) and NfL concentrations. A β 42/40 (IP-MS) concentrations showed significant positive, rather than negative, association with A β -PET SUVR in the temporal cortex (**Supplemental Figure 2**). In the CI group, voxel-wise regressions presented a significant positive association between A β -PET SUVR with plasma p-tau231 (but not p-tau181) and GFAP concentrations across the whole brain cortex after correction for multiple comparisons (**Figure 2A**). P-tau181 concentrations showed significant positive association with A β -PET in the precuneus and temporal cortex. No significant associations were observed between A β -PET with plasma A β 42/40 measured by Simoa and IP-MS or NfL concentrations in CI individuals after multiple comparison corrections.

3.4 Voxel-wise association of tau-PET SUVR with plasma biomarkers

In the CU group, voxel-wise regression indicated a significant positive association between tau-PET SUVR and p-tau231 in small clusters in the precuneus and temporal cortices and p-tau181 in the entorhinal cortex, after correction for multiple comparisons (**Figure 2B**). No significant association was observed between A β -PET and plasma A β 42/40 (Simoa/IP-MS), GFAP, and NfL concentrations in CU individuals. In the CI group, voxel-wise regressions indicated a significant positive association between tau-PET SUVR with plasma p-tau231 and GFAP concentrations across the brain cortex (**Figure 2B**). The p-tau181 and NfL concentrations showed widespread significant positive association with tau PET SUVR in the precuneus, frontal, and temporal cortices ($P < 0.05$). No significant association was found between tau-PET SUVR and plasma A β 42/40 (measured by Simoa and IP-MS) in CI individuals.

3.5 ROI-wise association of A β -PET SUVR with plasma biomarkers

In the CU group, we found a significant positive association between p-tau231, p-tau181 and GFAP concentrations and global A β -PET SUVR values (**Figure 3A**). No significant association was found between global A β -PET SUVR values and A β 42/40 (Simoa and IP-MS) and NfL values. The model using p-tau231 concentrations plus demographics as predictors explained the highest variability in the global A β -PET SUVR values (R-squared: 0.33). In the CI group, p-tau231, ptau181, and GFAP concentrations were significantly positive associated with global A β -PET SUVR. No significant association was found between global A β -PET SUVR and A β 42/40 (Simoa and IP-MS) and NfL. P-tau231 concentration plus demographics explained the highest variability in the global A β -PET SUVR values (R-squared: 0.30), closely followed by GFAP plus demographics (R-squared: 0.28) (**Supplemental Table 1**). Additional analysis adding to the model tau-PET SUVR as a covariate was performed, and the association between A β -PET SUVR and p-tau231 and GFAP in the CU group remained significant. However, it was insignificant in the CI group (**Supplemental Table 2**).

3.6 ROI-wise association of tau-PET SUVR with plasma biomarkers

In the CU group, p-tau231 was significantly associated with entorhinal tau-PET SUVR. No significant association was found with A β 42/40 (Simoa and IP-MS), p-tau181, GFAP, and NfL (**Figure 3B**). P-tau231 concentration plus demographics was the combination that best explains variability in the entorhinal tau-PET SUVR (R-squared: 0.15). In the CI group, entorhinal

cortex SUVR was significantly associated with p-tau231, p-tau181, NfL, and GFAP. No significant association was found with A β 42/40 (Simoa and IP-MS) values. P-tau231 plus demographics explained the highest variability in the entorhinal tau-PET SUVR (R-squared: 0.45), closely followed by GFAP plus demographics (R-squared: 0.44). Additional analysis adding to the model A β -PET SUVR as a covariate was performed, and the association between tau-PET SUVR and GFAP in the CI group remains significant while in the CU were not significant (**Supplemental Table 2**).

3.7 Prediction of A β -PET positivity with plasma biomarker concentrations

Plasma p-tau231 (alone or accounting for demographic characteristics) demonstrated higher performance in predicting A+ than demographics alone in the CU group ($P < 0.0001$; **Figure 4A**). On the other hand, A β 42/40 (Simoa and IP-MS), p-tau181, GFAP, and NfL (alone or accounting for demographic characteristics) did not show a significantly better predictive performance than demographics alone (95% confidence interval range: 0.615 – 0.811). DeLong test comparisons showed that the model including p-tau231 and demographics (AUC = 87.7%) was significantly better predictor than models including the other plasma makers (A β 42/40 (Simoa and IP-MS), p-tau181, GFAP, and NfL) alone (**Table 2**) or in combination with demographics (**Supplemental Table 3**). In the CI group, GFAP (alone or accounting for demographic characteristics) and p-tau231 (alone or accounting for demographic characteristics) showed higher performance than when only including demographics alone ($P < 0.0001$; **Figure 4B**) to detect A β positivity. On the other hand, A β 42/40 (Simoa and IP-MS), p-tau181, and NfL, (alone or accounting for demographic characteristics) did not show a better predictive performance than demographics alone (95% confidence interval range: 0.551 – 0.793). DeLong test comparison showed that the model including GFAP plus demographics (AUC = 93.6%) was significantly in predicting A+ better than the A β 42/40 (Simoa and IP-MS) p-tau231, p-tau181, and NfL alone (**Table 2**) or accounting for demographics (**Supplemental Table 3**).

3.8 Prediction of tau-PET positivity with plasma biomarker concentrations

In the CU group, p-tau231 (alone or accounting for demographic characteristics) and A β 42/40 (IP-MS) accounting for demographics presented a higher performance in predicting tau-PET positivity than demographics alone ($P < 0.05$; **Figure 4C**) to detect tau-PET positivity. In contrast, A β 42/40 (Simoa), p-tau181, and NfL (alone or accounting for demographic characteristics) did not show a better a better predictive performance than demographics alone

(95% confidence interval range: 0.579-0.761). DeLong test comparisons showed that the model including p-tau231 and demographics (AUC = 79.6%) was a significantly better predictor of tau-PET positivity than a model including with A β 42/40 (measured by Simoa and IP-MS), GFAP, and NfL alone (**Table 2**) or accounting for demographics (**Supplemental Table 3**). In the CI group, the models including GFAP, p-tau231, and p-tau181 (alone or accounting for demographic characteristics), NfL accounting for demographics showed a higher performance than demographics alone ($P < 0.0001$; **Figure 4D**) to predict tau-PET positivity. In contrast, A β 42/40 (Simoa and IP-MS) and NfL (alone or accounting for one or two demographics characteristics) did not show a better predictive performance than demographics alone (95% confidence interval range: 0.615-0.867). DeLong test comparisons showed that the model including GFAP plus demographics (AUC = 94.4%) was significantly better in predicting tau-PET positivity than the performance of models including A β 42/40 (Simoa and IP-MS), p-tau231, p-tau181, and NfL alone (**Table 2**) or with demographics (**Supplemental Table 3**).

4. Discussion

In this study, we compared plasma A β 42/40 (Simoa/IP-MS), p-tau, GFAP, and NfL biomarkers in the same individuals to identify A β - and tau-PET abnormality in the aging and AD dementia. We demonstrated that plasma p-tau, GFAP, and NfL significantly correlated with each other, while plasma A β 42/40 (Simoa/IP-MS) did not correlate with the other plasma markers. Our main findings were that plasma p-tau231 showed the best discriminative accuracy to both A β - and tau-PET positivity in CU, whereas plasma GFAP had the best discriminative accuracy to both A β - and tau-PET positivity in CI. In addition, we also demonstrated that including demographics (age, sex, and APOE ϵ 4) increases the discriminative performance of the plasma markers.

We observed that plasma A β 42/40 assays measured by both Simoa, and IP-MS did not correlate with other plasma markers and showed only a moderate ability to identify A β - and tau-PET positivity in CU and CI individuals. Specifically, we demonstrated that the addition of A β 42/40 (Simoa and IP-MS) did not increase the predictive performance of demographics (age, sex, and APOE ϵ 4) to identify A β - or tau-PET positivity. These results add to the conflicting literature in which some studies suggest that plasma A β 42 or A β 42/40 ratio strongly correlated with brain A β (AUC = 88 to 97%) [21, 25], while others suggest only a moderate association between plasma and PET assessments of A β [43, 44]. Moreover, previous

research revealed that IP-MS performed better than Simoa in terms of A β estimates [23], whereas we found similar discriminative accuracy using both techniques. Several biological and analytical factors may contribute to the divergence of our results. For example, biological factors such as peripheral A β expression accounts to >50% of the global plasma A β [45] and the modest fold-change between CU and CI in plasma (10–20%) compared to CSF A β (40–60%) may lead to the high susceptibility of plasma A β measures to small variabilities in pre-analytical approaches and cohorts characteristics [20, 21, 44]. In addition, differences in the analytical performance of distinct techniques used to measure plasma A β can also play a role in the difference in performance found across studies [23]. We have shown lack of robust correlation between plasma A β values and the other AD-related plasma markers. It is important to emphasize that although previous studies have shown a higher performance of plasma A β to detect brain A β than the presented here, to the best of our knowledge, no previous studies have shown a robust correlation between plasma A β and other plasma markers such as p-tau and GFAP. Altogether, these findings suggest that more studies are needed to elucidate the robustness of blood based A β assays to identify AD pathophysiology.

We show that plasma GFAP, compared to A β , p-tau, and NfL, better discriminates both A β - and tau-PET positivity in CI individuals. These results align with recent findings showing that GFAP levels progressively increase with AD progression [10, 16, 17]. Furthermore, the significant positive association between GFAP and A β -PET in CU individuals found in our study corroborated recent findings showing that GFAP levels are increased in individuals at risk of AD dementia [10, 46]. Interestingly, in CI group the GFAP levels were also highly associated with tau-PET positivity, independent of A β , in our study. Specifically, GFAP outperformed the p-tau markers to predict tau-PET positivity in the CI group. Because it has already been demonstrated that the association of GFAP with tau pathology is mediated by A β pathology [10], we speculate that the high performance of GFAP to predict tau-PET positivity is related to the fact that ~70% of the tau-positive individuals are also A β positive. However, we cannot exclude the possibility that GFAP's performance to identify tau-PET positivity is due to its increase in response to tau tangles deposition [47]. In addition, our findings and results from recent studies showing that plasma GFAP is closely linked to AD pathophysiology [10, 17, 46] suggest that this biomarker has the potential to be used for the categorization of individuals concerning their underlying pathological profiles in biomarker classification methods such as the AT(N) scheme [37, 48].

The study's main strength is the use of a well-characterized single cohort of individuals that underwent state-of-art harmonized biomarker acquisitions and quantifications. However, our findings should be viewed considering some limitations. The cohort used in this study is composed of individuals motivated to participate in a dementia study, potentially being a source of self-selection bias. Moreover, this study includes mostly White individuals, limiting the generalizability of our results to Black and Latinx populations. Previous studies suggest a negative association between A β 42/40 values and A β -PET uptake [49]. Here, we found a positive association between A β 42/40 IP-MS values and A β -PET in CU individuals. Future studies are being planned to elucidate the underpinnings of this unexpected positive association. Although previous studies suggest that plasma p-tau217 assays show better performance to detect AD dementia than p-tau181 and measurements of the plasma p-tau217 epitope were not available in our population. However, we have recently shown that plasma p-tau231 outperforms CSF p-tau217 to identify early changes in A β -PET [50].

5. Conclusion

To conclude, our results support plasma p-tau231 as an early marker of AD pathophysiology in asymptomatic individuals and GFAP as a robust marker of both A β and tau positivity in symptomatic individuals. These results highlight that the performance of plasma biomarkers to detect brain AD pathophysiology is disease stage specific.

Reference

- [1] Jack CR, Jr., Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. *Lancet Neurol.* 2013;12:207-16.
- [2] Jack CR, Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. *Alzheimers Dement.* 2018;14:535-62.
- [3] Morris JC, Schindler SE, McCue LM, Moulder KL, Benzinger TLS, Cruchaga C, et al. Assessment of Racial Disparities in Biomarkers for Alzheimer Disease. *JAMA Neurol.* 2019;76:264-73.
- [4] Molinuevo JL, Ayton S, Batrla R, Bednar MM, Bittner T, Cummings J, et al. Current state of Alzheimer's fluid biomarkers. *Acta Neuropathol.* 2018;136:821-53.
- [5] Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. *Ann Neurol.* 2004;55:306-19.
- [6] Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging: early progress and future directions. *Lancet Neurol.* 2015;14:114-24.
- [7] Villemagne VL, Doré V, Burnham SC, Masters CL, Rowe CC. Imaging tau and amyloid- β proteinopathies in Alzheimer disease and other conditions. *Nat Rev Neurol.* 2018;14:225-36.
- [8] Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. *Lancet Neurol.* 2020;19:422-33.
- [9] Karikari TK, Benedet AL, Ashton NJ, Lantero Rodriguez J, Snellman A, Suárez-Calvet M, et al. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative. *Mol Psychiatry.* 2021;26:429-42.
- [10] Benedet AL, Milà-Alomà M, Vrillon A, Ashton NJ, Pascoal TA, Lussier F, et al. Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. *JAMA Neurology.* 2021.

- [11] Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. *Jama*. 2020;324:772-81.
- [12] Mattsson-Carlsson N, Janelidze S, Palmqvist S, Cullen N, Svenningsson AL, Strandberg O, et al. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease. *Brain*. 2020;143:3234-41.
- [13] Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G, et al. Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. *Acta Neuropathol*. 2021;141:709-24.
- [14] Simpson JE, Ince PG, Lace G, Forster G, Shaw PJ, Matthews F, et al. Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain. *Neurobiol Aging*. 2010;31:578-90.
- [15] Oeckl P, Halbgebauer S, Anderl-Straub S, Steinacker P, Huss AM, Neugebauer H, et al. Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer's Disease and Correlates with Cognitive Impairment. *J Alzheimers Dis*. 2019;67:481-8.
- [16] Pereira JB, Janelidze S, Smith R, Mattsson-Carlsson N, Palmqvist S, Teunissen CE, et al. Plasma GFAP is an early marker of amyloid- β but not tau pathology in Alzheimer's disease. *Brain*. 2021.
- [17] Cicognola C, Janelidze S, Hertze J, Zetterberg H, Blennow K, Mattsson-Carlsson N, et al. Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. *Alzheimer's Research & Therapy*. 2021;13:68.
- [18] Mattsson N, Andreasson U, Zetterberg H, Blennow K. Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease. *JAMA Neurol*. 2017;74:557-66.
- [19] Ashton NJ, Janelidze S, Al Khleifat A, Leuzy A, van der Ende EL, Karikari TK, et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. *Nature Communications*. 2021;12:3400.
- [20] Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, et al. High-precision plasma β -amyloid 42/40 predicts current and future brain amyloidosis. *Neurology*. 2019;93:e1647-e59.

- [21] Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Doré V, et al. High performance plasma amyloid- β biomarkers for Alzheimer's disease. *Nature*. 2018;554:249-54.
- [22] De Meyer S, Schaevebeke JM, Verberk IMW, Gille B, De Schaepdryver M, Luckett ES, et al. Comparison of ELISA- and SIMOA-based quantification of plasma A β ratios for early detection of cerebral amyloidosis. *Alzheimers Res Ther*. 2020;12:162.
- [23] Janelidze S, Teunissen CE, Zetterberg H, Allué JA, Sarasa L, Eichenlaub U, et al. Head-to-Head Comparison of 8 Plasma Amyloid- β 42/40 Assays in Alzheimer Disease. *JAMA Neurol*. 2021.
- [24] Pannee J, Shaw LM, Korecka M, Waligorska T, Teunissen CE, Stoops E, et al. The global Alzheimer's Association round robin study on plasma amyloid β methods. *Alzheimers Dement (Amst)*. 2021;13:e12242.
- [25] Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, et al. Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2017;13:841-9.
- [26] Thijssen EH, Verberk IMW, Vanbrabant J, Koelewijn A, Heijst H, Scheltens P, et al. Highly specific and ultrasensitive plasma test detects Abeta(1-42) and Abeta(1-40) in Alzheimer's disease. *Sci Rep*. 2021;11:9736.
- [27] Sato C, Barthélemy NR, Mawuenyega KG, Patterson BW, Gordon BA, Jockel-Balsarotti J, et al. Tau Kinetics in Neurons and the Human Central Nervous System. *Neuron*. 2018;97:1284-98.e7.
- [28] Hampel H, O'Bryant SE, Molinuevo JL, Zetterberg H, Masters CL, Lista S, et al. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. *Nat Rev Neurol*. 2018;14:639-52.
- [29] Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. *JAMA Neurol*. 2019;76:791-9.
- [30] Hansson O, Janelidze S, Hall S, Magdalino N, Lees AJ, Andreasson U, et al. Blood-based NFL: A biomarker for differential diagnosis of parkinsonian disorder. *Neurology*. 2017;88:930-7.

- [31] Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE, Alvarez-Cermeño JC, et al. Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. *JAMA Neurol.* 2019;76:1035-48.
- [32] Chatterjee P, Pedrini S, Stoops E, Goozee K, Villemagne VL, Asih PR, et al. Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease. *Translational Psychiatry.* 2021;11:27.
- [33] Medeiros R, LaFerla FM. Astrocytes: conductors of the Alzheimer disease neuroinflammatory symphony. *Exp Neurol.* 2013;239:133-8.
- [34] Theriault J, Benedet AL, Pascoal TA, Savard M, Ashton NJ, Chamoun M, et al. Determining Amyloid- β Positivity Using (18)F-AZD4694 PET Imaging. *J Nucl Med.* 2021;62:247-52.
- [35] McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr., Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement.* 2011;7:263-9.
- [36] Pascoal TA, Theriault J, Benedet AL, Savard M, Lussier FZ, Chamoun M, et al. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles. *Brain.* 2020;143:2818-30.
- [37] Jack CR, Jr., Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, et al. Defining imaging biomarker cut points for brain aging and Alzheimer's disease. *Alzheimers Dement.* 2017;13:205-16.
- [38] Gisslén M, Price RW, Andreasson U, Norgren N, Nilsson S, Hagberg L, et al. Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study. *EBioMedicine.* 2015;3:135-40.
- [39] Mielke MM, Hagen CE, Xu J, Chai X, Vemuri P, Lowe VJ, et al. Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography. *Alzheimers Dement.* 2018;14:989-97.

- [40] Keshavan A, Pannee J, Karikari TK, Rodriguez JL, Ashton NJ, Nicholas JM, et al. Population-based blood screening for preclinical Alzheimer's disease in a British birth cohort at age 70. *Brain*. 2021;144:434-49.
- [41] Mathotaarachchi S, Wang S, Shin M, Pascoal TA, Benedet AL, Kang MS, et al. VoxelStats: A MATLAB Package for Multi-Modal Voxel-Wise Brain Image Analysis. *Front Neuroinform*. 2016;10:20.
- [42] Larsen WA, McCleary SJ. The Use of Partial Residual Plots in Regression Analysis. *Technometrics*. 1972;14:781-90.
- [43] Verberk IMW, Slot RE, Verfaillie SCJ, Heijst H, Prins ND, van Berckel BNM, et al. Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes. *Ann Neurol*. 2018;84:648-58.
- [44] Janelidze S, Stomrud E, Palmqvist S, Zetterberg H, van Westen D, Jeromin A, et al. Plasma β -amyloid in Alzheimer's disease and vascular disease. *Sci Rep*. 2016;6:26801.
- [45] Citron M, Vigo-Pelfrey C, Teplow DB, Miller C, Schenk D, Johnston J, et al. Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. *Proc Natl Acad Sci U S A*. 1994;91:11993-7.
- [46] Chatterjee P, Pedrini S, Stoops E, Goozee K, Villemagne VL, Asih PR, et al. Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease. *Transl Psychiatry*. 2021;11:27.
- [47] Garwood CJ, Ratcliffe LE, Simpson JE, Heath PR, Ince PG, Wharton SB. Review: Astrocytes in Alzheimer's disease and other age-associated dementias: a supporting player with a central role. *Neuropathol Appl Neurobiol*. 2017;43:281-98.
- [48] Hampel H, Cummings J, Blennow K, Gao P, Jack CR, Vergallo A. Developing the ATX(N) classification for use across the Alzheimer disease continuum. *Nature Reviews Neurology*. 2021;17:580-9.
- [49] Risacher SL, Fandos N, Romero J, Sherriff I, Pesini P, Saykin AJ, et al. Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition. *Alzheimers Dement (Amst)*. 2019;11:510-9.

[50] Karikari TK, Emeršič A, Vrillon A, Lantero-Rodriguez J, Ashton NJ, Kramberger MG, et al. Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis. *Alzheimers Dement*. 2021;17:755-67.

Funding

This research is supported by the Weston Brain Institute, Canadian Institutes of Health Research (#MOP-11-51-31; RFN 152985, 159815, 162303; PR-N), Canadian Consortium of Neurodegeneration and Aging (MOP-11-51-31 - team 1; PR-N), the Alzheimer's Association (#NIRG-12-92090, #NIRP-12-259245; PR-N), Brain Canada Foundation (CFI Project 34874; 33397; PR-N), the Fonds de Recherche du Québec – Santé (Chercheur Boursier, #2020-VICO-279314; PR-N). TAP, PR-N and SG are members of the CIHR-CCNA Canadian Consortium of Neurodegeneration in Aging. TAP is supported by the NIH (#R01AG075336 and #R01AG073267) and the Alzheimer's Association (#AACSF-20-648075). JPF-S receives financial support from CAPES [88887.627297/2021-00]. CT receives funding from Faculty of Medicine McGill and IPN McGill. DTL is supported by a NARSAD Young Investigator Grant from the Brain & Behavior Research Foundation (#29486). WSB is supported by CAPES (#88887.372371/2019-00 and #88887.596742/2020-00). JT is supported by the Canadian Institutes of Health Research & McGill Healthy Brains Healthy Lives initiative. ALB is supported by the Swedish Alzheimer Foundation, Stiftelsen för Gamla Tjänarinnor, and Stohne Stiftelsen. KB is supported by the Swedish Research Council (#2017-00915), the Alzheimer Drug Discovery Foundation (#RDAPB-201809-2016615), the Swedish Alzheimer Foundation (#AF-742881), Hjärnfonden (#FO2017-0243), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986), the European Union Joint Program for Neurodegenerative Disorders (#JPND2019-466-236), the NIH (#1R01AG068398-01), and the Alzheimer's Association 2021 Zenith Award (#ZEN-21-848495). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C), the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2019-0228), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), European Union Joint Program for Neurodegenerative Disorders (JPND2021-00694), and the UK Dementia Research Institute at UCL. TTK is funded by the Swedish Research Council's career establishment fellowship (#2021-03244), the Alzheimer's Association Research Fellowship (#850325), the BrightFocus Foundation (#A2020812F), the International Society for Neurochemistry's Career Development Grant, the Swedish Alzheimer Foundation (Alzheimerfonden; #AF-930627), the Swedish Brain Foundation (Hjärnfonden; #FO2020-0240), the Swedish Dementia Foundation (Demensförbundet), the Swedish Parkinson Foundation (Parkinsonfonden), Gamla Tjänarinnor Foundation, the Aina (Ann) Wallströms and Mary-Ann Sjöbloms Foundation, the Agneta Prytz-Folkes & Gösta Folkes Foundation (#2020-00124), the Gun and Bertil Stohnes Foundation, and the Anna Lisa and Brother Björnsson's Foundation. ERZ receives financial support from CNPq (#435642/2018-9 and #312410/2018-2), Instituto Serrapilheira (#Serra-1912-31365), Brazilian National Institute of Science and Technology in Excitotoxicity and Neuroprotection (#465671/2014-4), FAPERGS/MS/CNPq/SESRS-PPSUS (#30786.434.24734.231120170), and ARD/FAPERGS (#54392.632.30451.05032021) and Alzheimer's Association [AARGD-21-850670].

Competing interests

K.B. has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, all unrelated to the work presented in this paper. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, AZTherapies, CogRx, Denali, Eisai, Nervgen, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. S.G. has served as a scientific advisor to Cerveau Therapeutics. PCLF, CT, JPF-S, WSB, BB, DTL, JT, ALB, FZL, MC, GB, SS, JS, NR, VP, NMP, DLT, WEK, VLV, AC, ERZ, NJA, TKK, PR-N, TAP declare no competing interests.

Table 1. Demographics and characteristics of the population

	CU	CI		CU A-	CU A+		CI A-	CI A+		CU T-	CU T+		CI T-	CI T+	
	(N=138)	(N=87)	P value	(N=99)	(N=41)	P value	(N=19)	(N=72)	P value	(N=99)	(N=41)	P value	(N=19)	(N=72)	P value
Demographic characteristics															
Age, y ^a	71.7 (5.93)	69.8 (7.30)	0.06	70.7 (5.77)	75.4 (5.24)	< 0.0001	70.3 (6.97)	69.5 (7.16)	0.651	71.1 (6.11)	73.4 (5.09)	0.02	70.5 (7.65)	69.2 (7.49)	0.493
Education, y ^a	15.4 (3.69)	14.8 (3.53)	0.346	15.6 (3.73)	14.9 (3.28)	0.210	14.0 (3.71)	14.9 (3.29)	0.323	15.2 (3.56)	15.7 (3.87)	0.487	14.0 (3.45)	15.0 (3.47)	0.271
Female, No. (%)	95 (66.9)	48.0 (54.5)	0.756	99.0 (63.1%)	34.0 (75.6%)	0.167	11.0 (47.8%)	57.0 (54.3%)	0.028	63.0 (63.6%)	29.0 (70.7%)	0.542	11.0 (57.9%)	38.0 (52.8%)	0.889
APOE ε4, number (%)	39.0 (27.5)	42.0 (47.7)	0.002	39 (24.8%)	15.0 (33.3%)	0.345	5.0 (21.7%)	54.0 (51.4%)	0.74	23.0 (23.2%)	15.0 (36.6%)	0.159	2.0 (10.5%)	42.0 (58.3%)	< 0.0001
Cognition															
MMSE ^a	29.1 (1.18)	24.9 (5.41)	< 0.0001	29.3 (1.12)	29.1 (1.05)	0.445	28.3 (1.49)	23.6 (6.43)	< 0.0001	29.1 (1.09)	29.1 (1.41)	0.723	27.7 (1.59)	23.8 (5.99)	< 0.0001
Plasma measures, pg/mL															
p-tau231 ^a	14.7 (7.35)	22.1 (10.8)	< 0.0001	12.8 (5.74)	23.4 (13.1)	< 0.0001	12.3 (7.14)	24.1 (10.3)	< 0.0001	13.9 (7.28)	18.5 (11.4)	0.021	13.6 (7.33)	24.5 (10.7)	< 0.0001
p-tau181 ^a	10.8 (4.93)	18.7 (8.89)	< 0.0001	9.9 (4.09)	16.0 (12.1)	0.002	12.0 (6.53)	20.4 (9.45)	< 0.0001	10.4 (4.85)	13.9 (10.6)	0.05	13.4 (6.93)	20.8 (9.78)	< 0.0001
GFAP ^a	215 (112)	319.0 (170)	< 0.0001	187.0 (91.0)	296.0 (129)	< 0.0001	149.0 (63.2)	350.0 (160)	< 0.0001	210.0 (113)	236.0 (112)	0.226	190.0 (87.5)	353.0 (168)	< 0.0001
Aβ40 (Simoa) ^a	254 (62.3)	247.0 (56.5)	0.321	225.8 (54.8)	251.8 (52.3)	0.07	250.6 (67.8)	269.1 (60.6)	0.908	221.2 (55.9)	267.6 (45.91)	0.02	243.6 (59.7)	272.7 (62.6)	0.586

Aβ42 (Simoa) ^a	8.99 (2.98)	9.4 (3.07)	0.213	10.3 (3.21)	8.6 (3.21)	0.113	9.5 (3.2)	8.7 (2.93)	0.404	9.5 (3.2)	10.1 (2.93)	0.647	8.8 (3.1)	9 (3.0)	0.903
Aβ42/Aβ40 (Simoa) ^a	0.05 (0.20)	0.05 (0.19)	0.26	0.08 (0.301)	0.03 (0.01)	0.09	0.04 (0.010)	0.03 (0.010)	0.219	0.07 (0.28)	0.04 (0.01)	0.306	0.03 (0.01)	0.03 (0.009)	0.644
Aβ40 (IP-MS) ^a	279.0 (44.4)	279.0 (53.6)	0.861	252.7 (48.4)	279.7 (46.7)	0.580	300.8 (55.1)	277.1 (48.1)	0.06	260.7 (47.7)	278.9 (48.9)	0.880	309.3 (64.3)	278.1 (45.4)	0.03
Aβ42 (IP-MS) ^a	29.9 (14.0)	27.8 (13.7)	0.382	29.7 (12.6)	37.6 (36.2)	0.07	29.4 (7.6)	31.2 (14.8)	0.679	30.2 (13.8)	35.5 (30.6)	0.188	27.1 (14.5)	32.2 (14.6)	0.814
Aβ42/Aβ40 (IP-MS) ^a	0.11 (0.05)	0.11 (0.05)	0.756	0.11 (0.05)	0.104 (0.07)	0.709	0.09 (0.02)	0.102 (0.051)	0.345	0.12 (0.05)	0.11 (0.06)	0.726	0.09 (0.02)	0.11 (0.06)	0.173
NfL ^a	25.0 (16.9)	31.0 (13.2)	0.01	22.2 (9.36)	29.4 (22.1)	0.042	23.9 (8.45)	29.8 (12.1)	0.008	22.2 (9.36)	29.4 (22.1)	0.09	23.9 (8.45)	29.8 (12.1)	0.07
Neuroimaging															
[¹⁸ F]AZD4694 global SUVR ^a	1.6 (0.35)	2.20 (0.59)	< 0.0001	1.3 (0.09)	2.0 (0.341)	< 0.0001	1.3 (0.110)	2.4 (0.451)	< 0.0001	1.4 (0.28)	1.6 (0.47)	0.009	1.5 (0.44)	2.4 (0.48)	< 0.0001
Aβ+ (%)	23.0	81.0	-	0	100	-	0	100	-	0	100	-	0	100	-
[¹⁸ F]MK-6240 global SUVR ^a	1.1 (0.29)	2.2 (0.99)	< 0.0001	0.99 (0.224)	1.3 (0.478)	< 0.0001	0.95 (0.229)	2.4 (0.837)	< 0.0001	0.94 (0.17)	1.3 (0.42)	< 0.0001	0.93 (0.19)	2.5 (0.83)	< 0.0001
Tau + (%)	17.0	72.0	-	0	100	-	0	100	-	0	100	-	0	100	-

P values indicate the results of the analysis of variance to assesses difference between groups except for gender and APOE ε4 status where a contingency chi-square was performed. ^aMean (SD). CU = cognitively unimpaired, CI = cognitively impaired. Aβ = amyloid β. p-tau181 = tau phosphorylated at threonine 181, p-tau231 = tau phosphorylated at threonine 231, GFAP = glial fibrillary acidic protein, NfL = neurofilament light, MMSE Mini Mental State Examination. IP-MS = immunoprecipitation mass spectrometry.

Table 2. Performance of plasma biomarker to predict A β -PET and tau-PET positivity.

Biomarker	Predict A β -PET		Predict tau-PET	
	positivity		positivity	
	CU	CI	CU	CI
	AUC	AUC	AUC	AUC
Unadjusted				
A β 42/A β 40 Simoa	0.695	0.616	0.596	0.534
A β 42/A β 40 IP-MS	0.567	0.474	0.491	0.464
p-Tau231	0.844 ^{b,c,d,e,f}	0.789 ^{d,e}	0.739 ^e	0.832 ^{e,f}
p-Tau181	0.712 ^e	0.801 ^{d,e}	0.678 ^e	0.789 ^{d,e,f}
GFAP	0.763 ^{b,e}	0.904 ^{a,b,d,e,f}	0.625	0.851 ^{d,e}
NfL	0.684	0.626	0.627	0.646
Adjusted for age				
A β 42/A β 40 Simoa	0.761	0.672	0.751 ^e	0.682
A β 42/A β 40 IP-MS	0.679	0.743	0.734	0.775
p-Tau231	0.874 ^{b,c,d,e,f}	0.784 ^{d,e}	0.801 ^{c,d,e,f}	0.834 ^{d,e,f}
p-Tau181	0.749 ^e	0.796 ^{d,e}	0.750 ^{c,d,e,f}	0.772 ^{d,e,f}
GFAP	0.697	0.924 ^{a,b,d,e,f}	0.715 ^e	0.872 ^{d,e}
NfL	0.708	0.635	0.628	0.662
Adjusted for age, sex				
A β 42/A β 40 Simoa	0.734	0.712	0.756 ^e	0.677
A β 42/A β 40 IP-MS	0.703	0.743	0.761	0.776
p-Tau231	0.876 ^{b, c,d,e,f}	0.782 ^{d,e}	0.789 ^{c,d,e,f}	0.826 ^{e,f}
p-Tau181	0.758 ^{b,c,e}	0.782 ^{d,e}	0.751 ^{c,d,e,f}	0.771 ^{d,e,f}
GFAP	0.779	0.931 ^{a,b,d,e,f}	0.725 ^e	0.819 ^{a,b,d,e,f}
NfL	0.709	0.636	0.649	0.681
Adjusted for age, sex, APOE ϵ4 status				
A β 42/A β 40 Simoa	0.737	0.749	0.758 ^e	0.798

A β 42/A β 40 IP-MS	0.706	0.743	0.786	0.820
p-Tau231	0.877 ^{b,c,d,e,f}	0.821 ^{d,e}	0.796 ^{c,d,e,f}	0.921 ^{a,b,d,e,f}
p-Tau181	0.765 ^{b,c,e}	0.798 ^{d,e}	0.765 ^{c,e,f}	0.890 ^{b,d,e}
GFAP	0.788 ^e	0.936 ^{a,b,d,e,f}	0.698 ^e	0.944 ^{a,b,d,e,f}
NfL	0.732	0.731	0.733 ^e	0.865 ^{d,e,f}

DeLong test provided significant differences between groups with biomarker values: *a* compared to p-tau231; compared to p-tau181; *c* compared to GFAP; *d* compared to A β 42/A β 40 Simoa; *e* compared to A β 42/A β 40 IP-MS; *f* compared to NfL. Complete biomarker comparisons including the combinations of plasma biomarker values with demographic characteristics (age, sex, *APOE* ϵ 4) can be found in Supplementary Table 2.

A Pearson correlation matrix in CU

B Pearson correlation matrix in CI

C Distribution of plasma biomarker concentrations in CU

D Distribution of plasma biomarker concentrations in CI

Figure 1. Correlation coefficients and distribution of plasma biomarkers in CU and CI individuals. The panel on the top show the Pearson coefficients in CU (A) and CI (B) groups. The panel on the middle show the histograms with the distribution of each biomarker regarding their Aβ status in CU (C) and CI (D) groups. * Indicates the Pearson correlation coefficients that survived to Bonferroni correction for multiple comparison in each clinical group (15 tests, significant P value < 0.003). CU = Cognitively unimpaired, CI = Cognitively impaired. Histograms with the distribution of each biomarker regarding their Tau status are presented in Supplemental Figure 1.

Figure 2. Voxel-wise associations of $A\beta$ [^{18}F]AZD4694 SUVR and tau [^{18}F]MK-6240 SUVR with plasma biomarker concentrations in CU and CI individuals. The figure shows voxel-wise t-statistical maps of regressions between PET SUVR and plasma markers after RFT-correction for multiple comparisons at $P < 0.05$. Panel A shows the regions with a significant positive association between $A\beta$ [^{18}F]AZD4694 and plasma markers in CU and CI individuals. No significant negative associations were found after multiple comparison correction. The panel B shows the regions indicating a significant positive association between tau [^{18}F]MK-6240 SUVR and plasma markers in CU and CI individuals. No negative association was found between biomarkers after multiple comparison correction. The covariates included in the voxel-wise linear regression models were age, sex and APOE $\epsilon 4$. $A\beta 42/40$ measure by Simoa. Cognitively unimpaired, CI = Cognitively impaired. Voxel-wise association of [^{18}F]AZD4694 SUVR and tau [^{18}F]MK-6240 SUVR with plasma $A\beta 42/40$ measured by IP-MS can be found in Supplementary Figure 2.

A Aβ PET SUVR ~ Plasma biomarker + age + sex + APOE ε4 status.

B Tau PET SUVR ~ Plasma biomarker + age + sex + APOE ε4 status.

Figure 3. ROI-wise association of Aβ [¹⁸F]AZD4694 SUVR and tau [¹⁸F]MK-6240 SUVR with plasma biomarker values. The plots show the partial residual of ROI-based linear regressions testing the association between PET SUVR values (global Aβ value and entorhinal tau value) corrected by age, sex and APOE ε4 and plasma biomarker concentrations in CU (A) and CI (B). * Indicates the correlations that survived to Bonferroni correction for multiple comparison inside each clinical group (12 tests, corrected P value < 0.0042). CU = Cognitively unimpaired, CI = Cognitively impaired.

Figure 4. Performance of plasma markers to identify A β - and Tau-PET positivity. The plots on the left side show the AUC values for the prediction of A β -PET positivity using plasma biomarkers alone and adjusted for different demographics variable combinations in (A) CU and (B) CI individuals. The plots on the right side show the AUC values for predicting Tau-PET positivity of plasma biomarkers alone and adjusted for different demographics variable combinations in (C) CU and (D) CI individuals. The area in the rectangle represents 95% confidence interval of the model using all the demographic variables to predict PET positivity (age, sex, and APOE ϵ 4). CU = Cognitively unimpaired, CI = Cognitively impaired.